Business Wire

CO-ARROW-ELECTRONICS

9.6.2021 16:02:07 CEST | Business Wire | Press release

Share
Arrow Electronics and ROOQ Team to Innovate Sports Tracking

Global technology solutions provider Arrow Electronics (NYSE:ARW) and ROOQ, an innovator in sports measurement and analytics technology, have teamed up to create the ROOQ BOX, a sensor technology that enables boxers to monitor and review their performance using data that was previously only available under laboratory conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005194/en/

ROOQ BOX comprises a pair of sensors worn within a strap on each wrist. The sensors record the movements made during boxing activity. The data is then analyzed in the accompanying ROOQ app and cloud using machine learning algorithms to provide a precise record of the session. Using this information, boxers and trainers can create a detailed picture of the training session including punch count, punch speeds, variability and punch force. The algorithm has been trained to identify eight different types of punches and to automatically categorize these while filtering out non-boxing specific motions.

The data delivered by the sensor technology, which was inaccessible to athletes until now, provides an invaluable tool to help boxers monitor and improve their performance. This information can be shared with their coaches. In developing the system, ROOQ has drawn on a wide range of experience from within its team including data, software, hardware and firmware specialists, sports scientists and mathematicians as well as boxers and coaches. This experience reaches to the highest level: ROOQ’s chief sports officer, Henry Maske, is an Olympic boxing champion (gold medal, Seoul 1988) and professional world champion (1993 to 1996).

Arrow has been instrumental in leading the project in the firmware and hardware area between the suppliers of components, development and manufacturing services. Also, Arrow’s eInfochips engineering services were utilized in the project. Arrow has used its logistical and supply chain expertise to enable the product to be brought to market, and production scaled, in a smooth and efficient manner.

"This successful collaboration with ROOQ is a perfect example of how expert teams join forces and overcome difficult entrepreneurial challenges together," said Martin Bielesch, president of Arrow’s components business in EMEA. "Arrow's technical and logistical services enabled ROOQ to focus and execute on its leading competencies in delivering a completely new way of capturing diagnostic data in boxing."

Henry Maske sees many advantages in the cooperation between the two companies. "Arrow is a reliable and solution-oriented partner for us. We benefit from their immense experience as well as from their excellent global network.”

Boxing is just the beginning. The training diagnostics technology is universally applicable. Ralf Rüttgers, founder and CEO at ROOQ, is convinced that the application areas of ROOQ are manifold. He said, "Further development and transfer to the fitness market and other related sports, as well as use in the industrial sector, are all possible. Areas such as prevention, safety and health, will play a role in our future training analysis.”

About Arrow Electronics

Arrow Electronics guides innovation forward for over 180,000 leading technology manufacturers and service providers. With 2020 sales of $29 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com .

About ROOQ

ROOQ is about to enter the global market with its training analysis technology. The company employs an interdisciplinary team of over 25 people at its headquarters in Aachen, Germany. The technology model founded in 2018, is a novelty for boxing. For the first time, athletes and coaches receive individualized information on their training performance. For more information, visit rooq.de.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye